Press Releases

Date	Title	PDF Version
Jun 23, 2022	ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson disease community
May 05, 2022	ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
Apr 28, 2022	ULTOMIRIS® (ravulizumab-cwvz) approved in the US for adults with generalized myasthenia gravis
Apr 06, 2022	ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks
Jul 15, 2021	Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
Jun 11, 2021	Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Jun 07, 2021	Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 12, 2021	Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021
May 12, 2021	Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress
May 11, 2021	Alexion Shareholders Approve Acquisition by AstraZeneca

Search